desipramine has been researched along with Panic Disorder in 13 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of clomipramine hydrochloride (CMI), a serotonin reuptake inhibitor with the noradrenergic tricyclic antidepressant agent, and desipramine hydrochloride (DMI) for patients with panic disorder (PD)." | 9.09 | A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. ( Dannon, PN; Fux, M; Iancu, I; Sasson, Y; Taub, M; Zohar, J, 1999) |
| "This report is a descriptive summary of the relationship between response and plasma tricyclic concentrations found in our previously reported dose-ranging study of imipramine (IMI) in panic disorder (Mavissakalian & Perel 1995)." | 9.08 | The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder. ( Mavissakalian, MR; Perel, JM, 1996) |
| "Fifty-six males and females with panic disorder with or without agoraphobia participated in a 12-week, placebo-controlled treatment study of the efficacy of desipramine (DMI)." | 9.07 | Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. ( Ballenger, JC; Emmanuel, NP; Laraia, MT; Lydiard, RB; Morton, WA; O'Neil, PM; Stuart, GW; Zealberg, JJ, 1993) |
| "The authors report on seven consecutive openly treated patients with panic disorder who showed inadequate antipanic responses to treatment regimens including either a tricyclic (TCA) or fluoxetine." | 7.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "Thirteen patients meeting DSM-III-R criteria for panic disorder with or without agoraphobia that started during or shortly after cocaine exposure were treated in the UCLA Anxiety Disorders Program (Los Angeles, CA)." | 7.68 | Low dose desipramine treatment of cocaine-related panic attacks. ( Ackerman, DL; Bystritsky, A; Pasnau, RO, 1991) |
| "To compare the efficacy of clomipramine hydrochloride (CMI), a serotonin reuptake inhibitor with the noradrenergic tricyclic antidepressant agent, and desipramine hydrochloride (DMI) for patients with panic disorder (PD)." | 5.09 | A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. ( Dannon, PN; Fux, M; Iancu, I; Sasson, Y; Taub, M; Zohar, J, 1999) |
| "This report is a descriptive summary of the relationship between response and plasma tricyclic concentrations found in our previously reported dose-ranging study of imipramine (IMI) in panic disorder (Mavissakalian & Perel 1995)." | 5.08 | The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder. ( Mavissakalian, MR; Perel, JM, 1996) |
| "Fifty-six males and females with panic disorder with or without agoraphobia participated in a 12-week, placebo-controlled treatment study of the efficacy of desipramine (DMI)." | 5.07 | Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. ( Ballenger, JC; Emmanuel, NP; Laraia, MT; Lydiard, RB; Morton, WA; O'Neil, PM; Stuart, GW; Zealberg, JJ, 1993) |
| "The authors report on seven consecutive openly treated patients with panic disorder who showed inadequate antipanic responses to treatment regimens including either a tricyclic (TCA) or fluoxetine." | 3.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "Thirteen patients meeting DSM-III-R criteria for panic disorder with or without agoraphobia that started during or shortly after cocaine exposure were treated in the UCLA Anxiety Disorders Program (Los Angeles, CA)." | 3.68 | Low dose desipramine treatment of cocaine-related panic attacks. ( Ackerman, DL; Bystritsky, A; Pasnau, RO, 1991) |
| "Alprazolam and diazepam were associated with a lower dropout rate compared to placebo and were ranked as the most tolerated of all the medications examined." | 3.01 | Pharmacological treatments in panic disorder in adults: a network meta-analysis. ( Barbui, C; Bighelli, I; Caldwell, DM; Cipriani, A; Davies, SJ; Dawson, S; Dias, S; Furukawa, TA; Guaiana, G; Imai, H; Koesters, M; Meader, N; Pompoli, A; Robertson, L; Tajika, A, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (84.62) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Guaiana, G | 1 |
| Meader, N | 1 |
| Barbui, C | 1 |
| Davies, SJ | 1 |
| Furukawa, TA | 1 |
| Imai, H | 1 |
| Dias, S | 1 |
| Caldwell, DM | 1 |
| Koesters, M | 1 |
| Tajika, A | 1 |
| Bighelli, I | 1 |
| Pompoli, A | 1 |
| Cipriani, A | 1 |
| Dawson, S | 1 |
| Robertson, L | 1 |
| Vigliecca, NS | 1 |
| Molina, SC | 1 |
| Peñalva, MC | 1 |
| Villarreal, G | 1 |
| Tiffon, L | 1 |
| Coplan, JD | 1 |
| Papp, LA | 1 |
| Gorman, JM | 1 |
| Lydiard, RB | 1 |
| Morton, WA | 1 |
| Emmanuel, NP | 1 |
| Zealberg, JJ | 1 |
| Laraia, MT | 1 |
| Stuart, GW | 1 |
| O'Neil, PM | 1 |
| Ballenger, JC | 1 |
| Mavissakalian, MR | 1 |
| Perel, JM | 1 |
| Landry, P | 1 |
| Roy, L | 1 |
| Benazzi, F | 1 |
| Sasson, Y | 1 |
| Iancu, I | 1 |
| Fux, M | 1 |
| Taub, M | 1 |
| Dannon, PN | 1 |
| Zohar, J | 1 |
| Asnis, GM | 1 |
| Wetzler, S | 1 |
| Sanderson, WC | 1 |
| Kahn, RS | 1 |
| van Praag, HM | 1 |
| Pohl, R | 1 |
| Balon, R | 1 |
| Preskorn, SH | 1 |
| Fast, GA | 1 |
| Bystritsky, A | 1 |
| Ackerman, DL | 1 |
| Pasnau, RO | 1 |
1 review available for desipramine and Panic Disorder
| Article | Year |
|---|---|
Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Topics: Adult; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Clomipr | 2023 |
5 trials available for desipramine and Panic Disorder
| Article | Year |
|---|---|
Desipramine plasma levels and treatment response in panic disorder.
Topics: Desipramine; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Panic Disorder; Treatmen | 1995 |
Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder.
Topics: Adolescent; Adult; Aged; Desipramine; Double-Blind Method; Female; Humans; Male; Middle Aged; Panic | 1993 |
The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder.
Topics: Adult; Desipramine; Dose-Response Relationship, Drug; Female; Humans; Imipramine; Male; Panic Disord | 1996 |
A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Cross-Over Studies; Desipramine; Double-Blind | 1999 |
Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects.
Topics: Adult; Depressive Disorder; Desipramine; Female; Humans; Hydrocortisone; Male; Middle Aged; Norepine | 1992 |
7 other studies available for desipramine and Panic Disorder
| Article | Year |
|---|---|
[Multivariate study of the Open Field Drink Test using undernourished rats and desipramine as an antipanic drug].
Topics: Animals; Anti-Anxiety Agents; Conflict, Psychological; Desipramine; Dietary Proteins; Drinking Behav | 2007 |
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Desipramine; Drug Therapy, Combination; Female; | 1994 |
Withdrawal hypomania associated with paroxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bipolar Disorder; | 1997 |
Dangerous interaction with nefazodone added to fluoxetine, desipramine, venlafaxine, valproate and clonazepam combination therapy.
Topics: Adult; Antidepressive Agents; Clonazepam; Cyclohexanols; Depressive Disorder; Desipramine; Drug Ther | 1997 |
Antidepressants, panic disorder, and PTSD.
Topics: Adult; Desipramine; Female; Fluoxetine; Humans; Panic Disorder; Stress Disorders, Post-Traumatic | 1992 |
Tricyclic antidepressant-induced seizures and plasma drug concentration.
Topics: Adult; Ambulatory Care; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Desipr | 1992 |
Low dose desipramine treatment of cocaine-related panic attacks.
Topics: Adult; Cocaine; Desipramine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Mi | 1991 |